News & Analysis » US
MAP Pharma Reports Positive Safety Results For 12-month Open Label Trial Of Lavadex In Asthmatic, Non - Asthmatic Patients - Quick Facts
(RTTNews) - MAP Pharmaceuticals, Inc. (MAPP) today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX, an orally inhaled migraine therapy.
In this trial, LEVADEX has been well tolerated and no drug-related serious adverse events have been reported, the company said.
In addition, the company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application for LEVADEX. At this time, all patients have been enrolled in the company's clinical trials in support of an NDA, which the company expects to submit in the first half of 2011.
LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
Stock Market Forum
- Information about Stock trading - An Article
7 February 2012
- how do you find canada stocks to trade?
3 February 2012
- my stock to watch for tomorrow-CLD
3 February 2012
- Dynamic levels is all about showing the stock levels for last 12 years.
19 January 2012
- Bank of England Keeps Base Rate unaffected at 0.50%
13 January 2012
- Oil price rise fuels India's inflation
4 January 2012
- How to invest in stock market
27 December 2011
- Four Secrets to invest in Stock Market: Beginners Guide
27 December 2011
- Food inflation plunges to 4-year low of 1.81%
22 December 2011
- Nifty delete certain posts gains on GDP data
22 December 2011